Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program... Show more
HUM, the parent company of health insurer Humana, distributes its dividend on a quarterly schedule. The most recent quarterly payment of $0.885 per share brings the annualized payout to $3.54 per share, translating to a dividend yield of approximately 0.9% at recent share prices. That is a relatively modest yield by income standards, and it positions Humana less as a high-yield play and more as a slow-and-steady dividend payer within the managed-care sector. The company is generally viewed as a dividend-growth stock rather than an income stock, given its history of consistent annual increases over much of the past decade. However, with the quarterly rate unchanged since 2023, the near-term growth narrative has stalled even as the underlying payment has remained dependable.
Humana has a long record of returning cash to shareholders, with dividends paid since 1989 and a notable run of annual increases spanning roughly a decade. Between 2015 and 2023, the company lifted its quarterly dividend in steady steps—from about $0.28 per share to $0.885 per share—reflecting double-digit growth in many years. The most recent increase came in early 2023, when the quarterly rate rose from $0.7875 to $0.885. Since then, however, the dividend has been held flat, with no increase announced through 2025 and into 2026. As a result, the five-year compound annual growth rate (CAGR, the average yearly growth over a period) has slowed to roughly 5%–7%, and the trailing twelve-month growth rate is effectively zero. This pause reflects the company's shifting financial backdrop rather than a retreat from its commitment to the payout.
From a coverage standpoint, Humana's dividend appears sustainable. Based on adjusted earnings, the payout ratio is approximately 30%–35%, and the dividend consumes only about 22% of free cash flow (FCF, the cash a company generates after funding operations and capital spending). Both figures are conservative and leave a wide margin of safety for the current payout. The caution lies in the earnings trend itself: Humana's profitability has been pressured by higher medical costs and regulatory challenges in its Medicare Advantage business, which produced a sharp loss in late 2025. Earnings per share (EPS, the profit allocated to each outstanding share) have declined over the past several years. While the modest payout ratio suggests the dividend can be maintained through this turbulence, the weakening earnings base makes a return to meaningful dividend growth less likely in the near term. Management has kept the payout intact, signaling confidence in longer-term cash generation despite the near-term headwinds.
Within the health insurance industry, Humana's yield is on the lower end. Rival CVS Health offers a substantially higher yield, while UNH (UnitedHealth Group) and ELV (Elevance Health) pay yields that are modestly higher than Humana's. Several managed-care peers, including Centene and Molina Healthcare, pay no dividend at all, which makes Humana's reliable, if small, payout a differentiator for income-conscious investors. Compared with the broader healthcare sector, Humana's yield is below average, meaning the stock is unlikely to appeal to investors prioritizing current income. Its relative strength instead lies in a long payment record and a conservative payout ratio, which historically supported steady increases—even if that growth has recently paused.
Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF, a basket of securities that trades like a stock) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can also help identify dividend stocks, income-focused investments, trending stocks, and breakout candidates far more efficiently than manual research. For those researching companies like Humana or screening for reliable dividend payers across the healthcare sector, the tool offers a structured starting point for deeper analysis.
Humana is likely to appeal most to long-term, dividend-growth investors who prioritize a dependable, well-covered payout over a high current yield. Its roughly 0.9% yield is too low to satisfy investors who depend on dividend income, and the flat dividend since 2023 may deter those seeking steady increases. At the same time, the low payout ratio and long payment history provide a degree of comfort that the dividend is not at immediate risk, even amid earnings volatility. Conservative investors should weigh the ongoing pressures in the Medicare Advantage business, which have weighed on earnings and could delay future dividend growth. For investors who can tolerate cyclical swings in a blue-chip healthcare name and are focused on total return over a multi-year horizon, Humana's modest dividend represents a secondary, rather than primary, reason to own the shares. As always, individual goals and risk tolerance should guide any decision.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a company offers health insurance coverage and related services
Industry ManagedHealthCare